ECOG-ACRIN Cancer Research Group
ecog-acrin.orgLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
116
Active
50
Phase 3
25
Total enrollment
154,566
Pipeline matrix
Showing 40 of 69 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Cisplatin | — | — | — | 14 | |||
| Fluorouracil | — | — | — | — | 10 | ||
| Capecitabine | — | — | — | — | 6 | ||
| Carboplatin | — | — | — | 12 | |||
| Docetaxel | — | — | — | — | 7 | ||
| Lenalidomide | — | — | — | — | 4 | ||
| Leucovorin | — | — | — | — | 3 | ||
| Dexamethasone | — | — | — | — | — | 3 | |
| Pembrolizumab | — | — | — | — | 3 | ||
| Paclitaxel | — | — | — | 9 | |||
| leucovorin calcium | — | — | — | — | 5 | ||
| Gemcitabine | — | — | — | — | 4 | ||
| Gemcitabine Hydrochloride | — | — | — | — | 3 | ||
| Bortezomib | — | — | — | — | 3 | ||
| Oxaliplatin | — | — | — | — | — | 3 | |
| Goserelin Acetate | — | — | — | — | — | 2 | |
| Leuprolide Acetate | — | — | — | — | — | 2 | |
| Triptorelin | — | — | — | — | — | 2 | |
| rituximab | — | — | — | 5 | |||
| Floxuridine | — | — | — | — | — | 1 | |
| Irinotecan | — | — | — | — | — | 1 | |
| Panitumumab | — | — | — | — | — | 1 | |
| Bacillus Calmette Guerin | — | — | — | — | — | 1 | |
| Daratumumab and Hyaluronidase-fihj | — | — | — | — | — | 1 | |
| Standard of Care Chemotherapy | — | — | — | — | — | 1 | |
| Intraperitoneal Paclitaxel | — | — | — | — | — | 1 | |
| Apalutamide | — | — | — | — | — | 1 | |
| Degarelix | — | — | — | — | — | 1 | |
| Relugolix | — | — | — | — | — | 1 | |
| Darolutamide | — | — | — | — | — | 1 | |
| Carfilzomib | — | — | — | — | — | 1 | |
| Daratumumab | — | — | — | — | — | 1 | |
| Cabozantinib | — | — | — | — | — | 1 | |
| Dabrafenib | — | — | — | — | — | 1 | |
| Trametinib | — | — | — | — | — | 1 | |
| interferon alfa-2b | — | — | — | — | — | 1 | |
| Crizotinib | — | — | — | — | — | 1 | |
| Rituximab and Hyaluronidase Human | — | — | — | — | — | 1 | |
| bevacizumab | — | — | — | 6 | |||
| cetuximab | — | — | — | 3 |
29 more active programs hidden
Next readouts
- 2015-01
- 2020-11-30
- 2021-04-07
- 2021-05-26
- 2022-06-09
- 2023-09-19
- 2024-01-08
- 2025-04-23
- 2025-07-22
- 2026-03-02
Top conditions
- Lung Cancer9
- Leukemia7
- Lymphoma7
- Melanoma (Skin)5
- Head and Neck Cancer5
- Invasive Breast Carcinoma4
- Breast Cancer4
- Anatomic Stage II Breast Cancer AJCC v83
Frequently asked questions about ECOG-ACRIN Cancer Research Group
- How many clinical trials does ECOG-ACRIN Cancer Research Group have on ClinicalTrials.gov?
- ECOG-ACRIN Cancer Research Group is listed as the lead sponsor on 116 clinical trials in ClinicalTrials.gov, 50 of which are currently active (recruiting, enrolling, or ongoing).
- How many of ECOG-ACRIN Cancer Research Group's trials are in Phase 3?
- 25 of ECOG-ACRIN Cancer Research Group's trials are in Phase 3, spread across 69 active drug programs.
- What therapeutic areas does ECOG-ACRIN Cancer Research Group focus on?
- ECOG-ACRIN Cancer Research Group's most-studied conditions on ClinicalTrials.gov are Lung Cancer, Leukemia, Lymphoma, Melanoma (Skin), Head and Neck Cancer.
- When are ECOG-ACRIN Cancer Research Group's next clinical trial readouts?
- ECOG-ACRIN Cancer Research Group has 10 upcoming primary-completion readouts tracked here; the soonest is “High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma”, expected around 2015-01.